Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-09-19

AUTHORS

C G Roehrborn, P Ray

ABSTRACT

The efficacy and tolerability of dutasteride (0.5 mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians. More... »

PAGES

432-438

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.pcan.4500911

DOI

http://dx.doi.org/10.1038/sj.pcan.4500911

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021984943

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16983393


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "5-alpha Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "African Americans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azasteroids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dihydrotestosterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dutasteride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "European Continental Ancestry Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Linear Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Hyperplasia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Testosterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Retention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urodynamics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urologic Surgical Procedures, Male", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roehrborn", 
        "givenName": "C G", 
        "id": "sg:person.0767044373.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767044373.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Urology, Cook County Hospital, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.413120.5", 
          "name": [
            "Division of Urology, Cook County Hospital, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ray", 
        "givenName": "P", 
        "id": "sg:person.01171331567.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11934-001-0082-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005198537", 
          "https://doi.org/10.1007/s11934-001-0082-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00120-002-0230-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040076043", 
          "https://doi.org/10.1007/s00120-002-0230-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-09-19", 
    "datePublishedReg": "2006-09-19", 
    "description": "The efficacy and tolerability of dutasteride (0.5\u2009mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.pcan.4500911", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1119336", 
        "issn": [
          "1365-7852", 
          "1476-5608"
        ], 
        "name": "Prostate Cancer and Prostatic Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "phase III clinical trials", 
      "dual 5\u03b1-reductase inhibitor", 
      "tolerability of dutasteride", 
      "African Americans", 
      "serum dihydrotestosterone levels", 
      "benign prostatic hyperplasia", 
      "African American men", 
      "efficacy measures", 
      "safety profile", 
      "prostatic hyperplasia", 
      "dihydrotestosterone levels", 
      "clinical trials", 
      "similar efficacy", 
      "dutasteride", 
      "objective outcomes", 
      "significant treatment", 
      "tolerability", 
      "Caucasians", 
      "efficacy", 
      "race interaction", 
      "racial groups", 
      "treatment", 
      "hyperplasia", 
      "trials", 
      "analysis of data", 
      "outcomes", 
      "men", 
      "inhibitors", 
      "group", 
      "levels", 
      "measures", 
      "profile", 
      "data", 
      "analysis", 
      "interaction", 
      "III clinical trials"
    ], 
    "name": "Efficacy and tolerability of the dual 5\u03b1-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men", 
    "pagination": "432-438", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021984943"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.pcan.4500911"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16983393"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.pcan.4500911", 
      "https://app.dimensions.ai/details/publication/pub.1021984943"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_428.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.pcan.4500911"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500911'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500911'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500911'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500911'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      22 PREDICATES      90 URIs      80 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.pcan.4500911 schema:about N0d62d78250ed440f90af9f4102529195
2 N11baba7a069d426c95e291da14c46540
3 N1d9737671f834e5c961058cc37b35c72
4 N251d8473062d47c6beae462f450e8bd6
5 N25f4a36d52b444638fc822c7fc0fac7c
6 N29d28be577f849a58b405211660520a8
7 N3a2fc0e691234dbbb8a830a6953f02de
8 N43ac7c8b787f4f2092fc19b837db4f91
9 N57b2822fe26d4d9693aaf4d77fb63eb9
10 N5aa04e51762c4dfebbcc3317afe0a749
11 N5ac4785bfa7a4247a649cf14e65840be
12 N7ef72c35b27e4d5faf4499bed82f999d
13 N8078648870664dffab357b165df6d5a9
14 N83be84f1aa22443c88e88032671c7e7e
15 N87757aefbfc4412c89e95e8bdf0b51c1
16 N94130d269da74319ab5ae79e60922cc8
17 Nb98f13918d2c4a3e9b5bd452665a756a
18 Nbb5c1e4c488e49819df3d4948f910f98
19 Nc07194dc215a459aa5d947b197ab5b22
20 Nc19f36d0d73043d69e72286eca6d3d9c
21 Nc2bfb67d39d5499881a963daaee2dc92
22 Ncd89765435494e6aa62413d79307097b
23 Nd3f85bff2609468d985e7b7db32439e9
24 Ndd350c172086418cb244a87db79cd51a
25 Ne27705985087416a9ff07a2b965d4707
26 Nec1349b442cb439f90fcc9b1162f79ed
27 anzsrc-for:11
28 anzsrc-for:1103
29 schema:author Na2875abdc0704c2aa3b8a04fc2d8af16
30 schema:citation sg:pub.10.1007/s00120-002-0230-2
31 sg:pub.10.1007/s11934-001-0082-0
32 schema:datePublished 2006-09-19
33 schema:datePublishedReg 2006-09-19
34 schema:description The efficacy and tolerability of dutasteride (0.5 mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials. Dutasteride significantly reduced serum dihydrotestosterone levels by >90% and significantly improved subjective (symptom score) and objective (prostate volume, peak urinary flow rate, risk of benign prostatic hyperplasia-related surgery and acute urinary retention) outcomes in both African-Americans and Caucasians. For all efficacy measures, there was no statistically significant treatment-by-race interaction and dutasteride was well tolerated in both racial groups. Therefore, dutasteride demonstrated similar efficacy and safety profiles in African-Americans and Caucasians.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf Nb8e4c192818744468c75e343de86ebc7
39 Nf404d025c8bf47beb3c672e83f6679e8
40 sg:journal.1119336
41 schema:keywords African American men
42 African Americans
43 Caucasians
44 III clinical trials
45 analysis
46 analysis of data
47 benign prostatic hyperplasia
48 clinical trials
49 data
50 dihydrotestosterone levels
51 dual 5α-reductase inhibitor
52 dutasteride
53 efficacy
54 efficacy measures
55 group
56 hyperplasia
57 inhibitors
58 interaction
59 levels
60 measures
61 men
62 objective outcomes
63 outcomes
64 phase III clinical trials
65 profile
66 prostatic hyperplasia
67 race interaction
68 racial groups
69 safety profile
70 serum dihydrotestosterone levels
71 significant treatment
72 similar efficacy
73 tolerability
74 tolerability of dutasteride
75 treatment
76 trials
77 schema:name Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
78 schema:pagination 432-438
79 schema:productId N65fd309664c84fbaa7c31cda29573963
80 N9bf3c5d4a0064f25b2122aa03fde8bce
81 Ned5414eee1844cb79354e1f3bc7a4c1b
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021984943
83 https://doi.org/10.1038/sj.pcan.4500911
84 schema:sdDatePublished 2022-01-01T18:16
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N59a56806c19143d68864248dd974b12f
87 schema:url https://doi.org/10.1038/sj.pcan.4500911
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N0d62d78250ed440f90af9f4102529195 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Azasteroids
93 rdf:type schema:DefinedTerm
94 N11baba7a069d426c95e291da14c46540 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name European Continental Ancestry Group
96 rdf:type schema:DefinedTerm
97 N1d9737671f834e5c961058cc37b35c72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Prostatic Hyperplasia
99 rdf:type schema:DefinedTerm
100 N251d8473062d47c6beae462f450e8bd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name African Americans
102 rdf:type schema:DefinedTerm
103 N25f4a36d52b444638fc822c7fc0fac7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Testosterone
105 rdf:type schema:DefinedTerm
106 N29d28be577f849a58b405211660520a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Aged
108 rdf:type schema:DefinedTerm
109 N3a2fc0e691234dbbb8a830a6953f02de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Aged, 80 and over
111 rdf:type schema:DefinedTerm
112 N43ac7c8b787f4f2092fc19b837db4f91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N57b2822fe26d4d9693aaf4d77fb63eb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Severity of Illness Index
117 rdf:type schema:DefinedTerm
118 N59a56806c19143d68864248dd974b12f schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N5aa04e51762c4dfebbcc3317afe0a749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Double-Blind Method
122 rdf:type schema:DefinedTerm
123 N5ac4785bfa7a4247a649cf14e65840be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 N65fd309664c84fbaa7c31cda29573963 schema:name dimensions_id
127 schema:value pub.1021984943
128 rdf:type schema:PropertyValue
129 N7ef72c35b27e4d5faf4499bed82f999d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Biomarkers
131 rdf:type schema:DefinedTerm
132 N8078648870664dffab357b165df6d5a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Prostate-Specific Antigen
134 rdf:type schema:DefinedTerm
135 N83be84f1aa22443c88e88032671c7e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Urologic Surgical Procedures, Male
137 rdf:type schema:DefinedTerm
138 N87757aefbfc4412c89e95e8bdf0b51c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Linear Models
140 rdf:type schema:DefinedTerm
141 N94130d269da74319ab5ae79e60922cc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Acute Disease
143 rdf:type schema:DefinedTerm
144 N9848bdf4f92645f2b6897be48f404331 rdf:first sg:person.01171331567.29
145 rdf:rest rdf:nil
146 N9bf3c5d4a0064f25b2122aa03fde8bce schema:name pubmed_id
147 schema:value 16983393
148 rdf:type schema:PropertyValue
149 Na2875abdc0704c2aa3b8a04fc2d8af16 rdf:first sg:person.0767044373.20
150 rdf:rest N9848bdf4f92645f2b6897be48f404331
151 Nb8e4c192818744468c75e343de86ebc7 schema:volumeNumber 9
152 rdf:type schema:PublicationVolume
153 Nb98f13918d2c4a3e9b5bd452665a756a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Enzyme Inhibitors
155 rdf:type schema:DefinedTerm
156 Nbb5c1e4c488e49819df3d4948f910f98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Dutasteride
158 rdf:type schema:DefinedTerm
159 Nc07194dc215a459aa5d947b197ab5b22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Urination
161 rdf:type schema:DefinedTerm
162 Nc19f36d0d73043d69e72286eca6d3d9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Proportional Hazards Models
164 rdf:type schema:DefinedTerm
165 Nc2bfb67d39d5499881a963daaee2dc92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Dihydrotestosterone
167 rdf:type schema:DefinedTerm
168 Ncd89765435494e6aa62413d79307097b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Urinary Retention
170 rdf:type schema:DefinedTerm
171 Nd3f85bff2609468d985e7b7db32439e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Urodynamics
173 rdf:type schema:DefinedTerm
174 Ndd350c172086418cb244a87db79cd51a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name 5-alpha Reductase Inhibitors
176 rdf:type schema:DefinedTerm
177 Ne27705985087416a9ff07a2b965d4707 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Treatment Outcome
179 rdf:type schema:DefinedTerm
180 Nec1349b442cb439f90fcc9b1162f79ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Male
182 rdf:type schema:DefinedTerm
183 Ned5414eee1844cb79354e1f3bc7a4c1b schema:name doi
184 schema:value 10.1038/sj.pcan.4500911
185 rdf:type schema:PropertyValue
186 Nf404d025c8bf47beb3c672e83f6679e8 schema:issueNumber 4
187 rdf:type schema:PublicationIssue
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
192 schema:name Clinical Sciences
193 rdf:type schema:DefinedTerm
194 sg:journal.1119336 schema:issn 1365-7852
195 1476-5608
196 schema:name Prostate Cancer and Prostatic Diseases
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01171331567.29 schema:affiliation grid-institutes:grid.413120.5
200 schema:familyName Ray
201 schema:givenName P
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29
203 rdf:type schema:Person
204 sg:person.0767044373.20 schema:affiliation grid-institutes:grid.267313.2
205 schema:familyName Roehrborn
206 schema:givenName C G
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767044373.20
208 rdf:type schema:Person
209 sg:pub.10.1007/s00120-002-0230-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040076043
210 https://doi.org/10.1007/s00120-002-0230-2
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s11934-001-0082-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005198537
213 https://doi.org/10.1007/s11934-001-0082-0
214 rdf:type schema:CreativeWork
215 grid-institutes:grid.267313.2 schema:alternateName Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
216 schema:name Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
217 rdf:type schema:Organization
218 grid-institutes:grid.413120.5 schema:alternateName Division of Urology, Cook County Hospital, Chicago, IL, USA
219 schema:name Division of Urology, Cook County Hospital, Chicago, IL, USA
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...